Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market to expand at a CAGR of 7.2% from 2022 to 2030

The global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market for the historical period 2017–2018 and forecast period 2019–2027, rise in prevalence of cystic fibrosis and chronic pancreatitis to escalate the growth of global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market. Moreover, rising cases of diabetes are expected to fuel growth of the exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market

According to the report, the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market was valued at US$ 3.9 Bn in 2018 and is anticipated to expand at a CAGR of 7.2% from 2019 to 2030

Rise in Focus on Research & Development and Surge in Number of People with Diabetes Mellitus: Key Drivers of Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market

Get the sample copy of report@ https://qyresearchmedical.com/sample/111657

EPI is caused by insufficient secretion of pancreatic enzymes such as amylase, lipase, and protease and/ or sodium bicarbonate. Several disorders including different types of diabetes are associated with significantly increased risk for exocrine pancreatic insufficiency (EPI). For instance, according to an article published in Current Diabetes Reports, states that the prevalence of exocrine pancreatic insufficiency (EPI) is higher in type 1 diabetes than in type 2 diabetes. Thus, surge in number of people with diabetes is a key factor anticipated to drive the growth of exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market

Sedentary lifestyle and unhealthy diet are leading to surge in prevalence & incidence of diabetes. For instance, according to an article published in Diabetes Research and Clinical Practice, globally the prevalence of diabetes was 463 million in 2019 and is rising to 578 million by 2030

This is augmenting the demand for new treatment. To address these demands, the key players are investing in the research and development activities to develop and introduce new exocrine pancreatic insufficiency therapeutics thereby boosting the growth of market. For instance, AzurRx is developing a yeast-derived lipase, MS1819, which has been engineered to have superior enzymatic activity as compared to current treatments

Get a glimpse of the in-depth analysis through our Report Brochure

Increase in Prevalence of Chronic Pancreatitis and Cystic Fibrosis Propel Global Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Growth

Cystic fibrosis is the most common cause of exocrine pancreatic insufficiency. Around 50% of infants with cystic fibrosis have exocrine pancreatic insufficiency at birth, and another 25% develop it within six months. An additional 15% develop exocrine pancreatic insufficiency sometime in childhood or early adulthood.

Thus, rise in the global incidence of cystic fibrosis and chronic pancreatitis is one of the major factors driving the exocrine pancreatic insufficiency therapeutics & diagnostics market

View full report@ https://qyresearchmedical.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-market-therapeutics-and-diagnostics-blood-tests-endoscopic-ultra-sonography-magnetic-resonance-imaging-mri-and-ct-scanning-global-indust-019-2030/111657

Stringent FDA Regulations to Hamper Global Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market

Pancreatic enzyme replacement therapy (PERT) using pancrelipase products, which are mostly purified from the porcine pancreas, has been tested widely for exocrine pancreatic insufficiency associated with pancreatic diseases. Pancreatic enzyme products have been available as over-the-counter drugs in many regions for several years.

However, some drug regulatory agencies, including the U.S. Food and Drug Administration (FDA), have instructed that manufacturers obtain regulatory approvals before marketing their products because of possible adverse effects and inadequate effectiveness. These stringent FDA regulations have made approval of pancrelipase products difficult. This is leading to restrain the growth of market

Global Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market: Competitive Landscape

This report profiles major players in the global exocrine pancreatic insufficiency therapeutics & diagnostics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments

The global exocrine pancreatic insufficiency therapeutics & diagnostics market is highly fragmented, with the presence of a number of international as well as regional players

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111657/2900

Leading players operating in the global exocrine pancreatic insufficiency therapeutics & diagnostics market

  • AbbVie, Inc
  • Allergan plc.
  • Nordmark Arzneimittel GmbH & Co. KG
  • Digestive Care, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Cilian AG
  •  Anthera Pharmaceuticals, Inc
  • AzurRx Biopharma, Inc.

Key Questions Answered in Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Report

  • What is the scope of growth for product companies in the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market?
  • What will be the Y-o-Y growth of the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market between 2019 and 2027?
  • What is the influence of changing trends in technologies on the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market?
  • Will North America continue to be the most profitable market for exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics providers?
  • Which factors are anticipated to hamper the growth of the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market during the forecast period?
  • Which are the leading companies in the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market?

Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market – Segmentation

Type

  • Therapeutics
  • Diagnostics
  • Blood Tests
  • Endoscopic Ultra-sonography (EUS)
  • Magnetic Resonance Imaging (MRI)
  • CT Scanning

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

TABLE OF CONTENT

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market

4. Market Overview

4.1. Introduction

4.1.1. Type/Definition

4.1.2. Industry Evolution / Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Analysis and Forecasts, 2017–2027

5. Key Insights

5.1. Brand Analysis

5.2. Pipeline Analysis

5.3. Key Industry Events

6. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Analysis and Forecasts, by Type

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Value Forecast By Type, 2017–2027

6.3.1. Therapeutics

6.3.2. Diagnostics

6.3.2.1. Blood Tests

6.3.2.2. Endoscopic Ultra-sonography (EUS)

6.3.2.3. Magnetic Resonance Imaging (MRI)

6.3.2.4. CT Scanning

6.4. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Attractiveness by Type

7. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Analysis and Forecasts, by Region

7.1. Key Findings

7.2. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Value Forecast by Region

7.2.1. North America

7.2.2. Europe

7.2.3. Asia Pacific

7.2.4. Latin America

7.2.5. Middle East & Africa

7.3. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Attractiveness by Country/Region

8. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Analysis and Forecast

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111657/2900

You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333

About Us

QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.

For Latest Update Follow Us:

https://www.linkedin.com/company/qyresearch-medical/

https://www.facebook.com/QYResearch-Medical-108186514228917/

https://twitter.com/qyresearchmedi